---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-25-000131"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:32:10.107654+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BeOne Medicines Q2 2025 revenues jump 42% to $1.3B; GAAP EPS $0.84

## Summary
- Total revenues $1.315B vs $929M YoY (+42%); BRUKINSA revenues up 49% to $950M.
- GAAP net income $94.3M ($0.84 diluted EPS/ADS) vs loss of $120.4M a year ago.
- Non-GAAP diluted EPS $2.25, adjusted income from operations $274.9M (up 467% YoY).
- Free cash flow positive $219.8M vs negative $205.5M in Q2 2024.
- Company expects 20+ R&D milestones in next 18 months across hematology and solid tumors.

## SEC filing metadata
- accession: 0001651308-25-000131
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000131/0001651308-25-000131-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130825000131/bgne-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-25-000131
- JSON: https://secwatch.observer/filing/0001651308-25-000131.json
- Plain text: https://secwatch.observer/filing/0001651308-25-000131.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.